Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-NK in Relapsed or Refractory Multiple Myeloma
NCT06242249Phase 2Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA-CAR NK in multiple myeloma (MM), sponsored by Shahid Beheshti University of Medical Sciences. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
BCMA-CAR NK
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06242249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242249.